muscle cramp/karcinom prsu

Odkaz je uložen do schránky

Vyberte typ řazení

Strana 1 z 45 Výsledek

[Case of antiamphiphysin antibody-positive stiff-person syndrome with breast cancer diagnosed by FDG-PET].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

We report a case of antiamphiphysin antiboddy-positive stiff-person syndrome associated with breast cancer, which was detected only by FDG-PET. A 46-year-old woman was admitted to our hospital because of painful muscle cramp and stiffness of both legs. Laboratory results were negative for anti-GAD

[Steady state and disappearance of the metabolites of miproxifene phosphate in the treatment of breast cancer].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

We gave miproxifene phosphate to six patients with recurrent breast cancer and to one patient with advanced breast cancer. This drug was orally administered at a daily dose of 20 mg in the morning, and serial blood samples were obtained just before the drug administration. Treatment was discontinued

Advanced breast cancer: response to high dose oral medroxyprogesterone acetate.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

We treated 105 patients with advanced breast cancer, using the progestational agent medroxyprogesterone acetate (MPA), 200 mg orally tds in a non-randomised trial. In general they were a poor risk population, since 78 had received prior endocrine therapy (21 more than one type) and 58 prior

Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Thirty-nine evaluable, postmenopausal patients with metastatic breast carcinoma were treated with medroxyprogesterone acetate administered orally at daily doses of 800 mg/day in 29 patients and 400 mg/day in 10 patients. One patient experienced a complete remission and 16 had partial remissions for

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

The Generations trial, a multicenter, placebo-controlled, double-blind trial, compared arzoxifene 20 mg/day and placebo in 9,354 postmenopausal women with osteoporosis (N=5,252) or low bone mass (N=4,102). Primary outcomes were vertebral fracture in the osteoporotic population and invasive breast

Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Thirty-two patients with advanced breast cancer were treated with mitomycin-C 10 mg/m2 IV and vinblastine 6 mg/m2 IV every 21 days in combination with lonidamine 450 mg/day P.O. and prednisone 15 mg/day P.O. given continuously. Among the 29 evaluable patients (all but three pretreated with an

Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

In a multicenter trial, 123 patients with advanced breast cancer who had been treated with tamoxifen and/or chemotherapy were randomized to receive medroxyprogesterone acetate (MPA) orally 300 mg X 3 daily or im 500 mg daily for 4 weeks and 500 mg X 2 weekly thereafter. All case histories were

Chemoprevention of breast cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

OBJECTIVE The risk factors for and risk assessment of breast cancer, recommendations for risk reduction, and roles of tamoxifen and raloxifene in the prevention of breast cancer are discussed. CONCLUSIONS Breast cancer either may be a familial syndrome or develop sporadically. In familial syndromes,

Paraneoplastic sensorimotor neuropathy associated with breast cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Paraneoplastic sensorimotor neuropathy occurs in association with many different types of cancer. The clinical findings are heterogeneous, and the pathogenesis is unknown. We have encountered 9 women with breast cancer and shared neurological features that suggest a distinct paraneoplastic syndrome.

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

In premenopausal women, tamoxifen for 5 years reduces the risk of estrogen receptor (ER) - positive breast cancer for at least 10 years. Women < 50 years of age experience fewer serious side effects. Vascular and vasomotor events do not persist after treatment regardless of age. Raloxifene use is

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Risk factors allow us to define women who are at increased lifetime risk for breast cancer, and the most important factor is age. Benign breast disease increases risk, and the most important histologies are atypical lobular or ductal hyperplasia and lobular carcinoma in situ. Family history of

Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Thirty nine patients with metastatic breast cancer, all previously treated with chemotherapy including anthracycline, were given Elliptinium acetate (80 mg/m2/day) and a continuous infusion of Vinblastine (2 mg/m2/day) for 3 consecutive days every 4 weeks. Twenty nine patients had measurable

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown. OBJECTIVE To compare the differences in patient-reported outcomes, quality of life [QOL], and symptoms in Study of Tamoxifen and Raloxifene (STAR)

Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND Approximately 2000 American men are diagnosed with breast cancer every year. Limited data are available evaluating toxicity of antihormonal treatments in male breast cancer patients. METHODS We reviewed male breast cancer patients evaluated at our institution (1999-2009). Of 126 patients,

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

The purpose of this study was to assess the feasibility of using the selective estrogen receptor modulator (SERM) acolbifene as a breast cancer prevention agent in premenopausal women. To do so, we assessed change in proliferation in benign breast tissue sampled by random periareolar fine-needle

Předchozí
1
2
3
další

Připojte se k naší
facebookové stránce

Herbal & Natural Medicine

Nejúplnější databáze léčivých bylin podložená vědou

Funguje v 55 jazycích
Bylinné léky podporované vědou
Rozpoznávání bylin podle obrázku
Interaktivní mapa GPS - označte byliny na místě (již brzy)
Přečtěte si vědecké publikace související s vaším hledáním
Hledejte léčivé byliny podle jejich účinků
Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty

Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu